<?xml version="1.0" encoding="UTF-8"?>
<p>More than 700 million doses of azithromycin have been distributed to trachoma-endemic districts as part of trachoma control.
 <sup>
  <xref rid="b1" ref-type="bibr">1</xref>
 </sup> Annual mass drug administration (MDA) with azithromycin dramatically reduces the prevalence of 
 <italic>Chlamydia trachomatis</italic>, the causative organism of trachoma.
 <sup>
  <xref rid="b2" ref-type="bibr">2</xref>,
  <xref rid="b3" ref-type="bibr">3</xref>
 </sup> Collateral effects of azithromycin MDA may include reduction in infectious burden, including malaria parasitemia,
 <sup>
  <xref rid="b4" ref-type="bibr">4</xref>,
  <xref rid="b5" ref-type="bibr">5</xref>
 </sup> upper respiratory infection,
 <sup>
  <xref rid="b6" ref-type="bibr">6</xref>
 </sup> and diarrhea,
 <sup>
  <xref rid="b7" ref-type="bibr">7</xref>
 </sup> and improving nutritional status.
 <sup>
  <xref rid="b8" ref-type="bibr">8</xref>â€“
  <xref rid="b10" ref-type="bibr">10</xref>
 </sup> Unintended but beneficial effects of mass azithromycin distribution may lead to improvements in child health at the population level that extend beyond those for trachoma control.
</p>
